These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 22810444)
1. Adaptive Bayesian randomized trials: realizing their potential. Pullenayegum EM J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():29-33. PubMed ID: 22810444 [TBL] [Abstract][Full Text] [Related]
2. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization. Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191 [TBL] [Abstract][Full Text] [Related]
3. Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Connor JT; Luce BR; Broglio KR; Ishak KJ; Mullins CD; Vanness DJ; Fleurence R; Saunders E; Davis BR Clin Trials; 2013 Oct; 10(5):807-27. PubMed ID: 23983160 [TBL] [Abstract][Full Text] [Related]
4. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example. Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354 [TBL] [Abstract][Full Text] [Related]
5. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Willan A; Kowgier M Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843 [TBL] [Abstract][Full Text] [Related]
6. A Bayesian adaptive design approach for stepped-wedge cluster randomized trials. Wang J; Cao J; Ahn C; Zhang S Clin Trials; 2024 Aug; 21(4):440-450. PubMed ID: 38240270 [TBL] [Abstract][Full Text] [Related]
8. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Shen W; Ning J; Yuan Y Stat Med; 2015 Jun; 34(13):2104-15. PubMed ID: 25756852 [TBL] [Abstract][Full Text] [Related]
9. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test. Yu Q; Zhu L; Zhu H Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435 [TBL] [Abstract][Full Text] [Related]
10. A Bayesian adaptive blinded sample size adjustment method for risk differences. Hartley AM Pharm Stat; 2015; 14(6):488-514. PubMed ID: 26403845 [TBL] [Abstract][Full Text] [Related]
11. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups. Kikuchi T; Gittins J Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784 [TBL] [Abstract][Full Text] [Related]
12. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study. Ryan EG; Lamb SE; Williamson E; Gates S Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341 [TBL] [Abstract][Full Text] [Related]
13. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test. Shan G; Ma C; Hutson AD; Wilding GE J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517 [TBL] [Abstract][Full Text] [Related]
14. Early Termination of Randomized Clinical Trials in Orthopaedics. Piuzzi N; Chughtai M; Khlopas A; Gwam CU; Muschler G; Spindler KP; Mont MA Surg Technol Int; 2017 Feb; 30():290-294. PubMed ID: 28182822 [TBL] [Abstract][Full Text] [Related]
15. Simulation study for evaluating the performance of response-adaptive randomization. Du Y; Wang X; Jack Lee J Contemp Clin Trials; 2015 Jan; 40():15-25. PubMed ID: 25460340 [TBL] [Abstract][Full Text] [Related]
16. The sample size for a clinical trial: a Bayesian-decision theoretic approach. Halpern J; Brown BW; Hornberger J Stat Med; 2001 Mar; 20(6):841-58. PubMed ID: 11252007 [TBL] [Abstract][Full Text] [Related]
17. Bayesian evaluation of group sequential clinical trial designs. Emerson SS; Kittelson JM; Gillen DL Stat Med; 2007 Mar; 26(7):1431-49. PubMed ID: 17066402 [TBL] [Abstract][Full Text] [Related]
18. Adaptive design and estimation in randomized clinical trials with correlated observations. Yin G; Shen Y Biometrics; 2005 Jun; 61(2):362-9. PubMed ID: 16011682 [TBL] [Abstract][Full Text] [Related]
19. Early stopping rules in oncology: considerations for clinicians. Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153 [TBL] [Abstract][Full Text] [Related]
20. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Xie F; Ji Y; Tremmel L Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]